Research Project
Grant-in-Aid for Scientific Research on Priority Areas
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. The major component of the plaques, amyloid β peptide (Aβ), is generated from amyloid precursor protein (APP) by β-and γ. secretase-mediated cleavages. Since BACE1 (β-site APP cleaving enzyme 1)-knockout mice produce much less Aβand grow healthily without apparent side effects, BACE1 inhibitor is thought to be one of the most attractive targets for the development of therapeutic interventions for AD.Here, we report in vivo inhibitory effects of a novel BACE1 inhibitor, KMI-429, which is a transition-state mimic, effectively inhibits β- secretase activity in cultured cells in a dose-dependent manner. We injected KMI.429 into the hippocampus of APP transgenic and wild-type mice and measured the release of sAPPβ (soluble extracellular fragment of APP generated by β-secretase), the level of APP-CTF (C-terminal fragment of APP) and Aβ level by quantitative Western blotting and sandwitch ELISA. KMI.429 significantly reduced Aβ production in soluble fraction compared with vehicle in vivo, but changes in Aβ levels in insoluble fraction were not so affected. In contrast, the intrahippocampal injection of KMI.429 in wild-type mice remarkably reduced Aβ production in both soluble and insoluble fractions. Our results indicate that the BACE1 inhibitor KMI.429 would be a promising candidate for a treatment for AD.
All 2005 2004 2003 2002 2001 2000 Other
All Journal Article (57 results) Book (5 results) Publications (16 results)
Neurology 64
Pages: 687-692
J.Biochem. 137
Pages: 205-216
10017343257
Biochim.Biophys.Acta 1748
Pages: 174-179
Pages: 495-502
10017344589
J.Neurochem. 94(in press)
Pages: 1146-1157
J.Neurochem. 94
Biochem.Biophys.Res.Commun 314
Pages: 730-736
J.Biochem. 314
Pages: 1008-1013
Human Mol.Genet. 13
Pages: 495-507
Bioorg. Med. Chem. Lett. 14
Pages: 1527-1531
J.Biol.Chem. 278
Pages: 21217-21222
ASSAY and Drug Development Technologies 2
Pages: 383-388
Eur.J.Pharmacol. 500
Pages: 159-166
Biochem.Biophys.Res.Commun. 314
Bioorg.Med.Chem.Lett. 14
J.Biol.Chem. 279
ASSAY and Drug Development Technologies. 2
Biochem.Biophys.Res.Commun. 301
Pages: 231-235
J.Biochem. 134
Pages: 57-61
10012056067
Pages: 24294-24301
J.Neurochem. 86
Pages: 869-878
Bioorg. Med. Chem. Lett. 13
Pages: 4273-4276
Bioorg.Med.Chem.Lett. 13
Neurosci.Lett. 319
Pages: 13-16
J.Biochem. 131
Pages: 647-651
10010647759
Biochem.Biophys.Res. Commun. 293
Pages: 800-805
Biochem.Biophys.Res.Commun. 293
Pages: 1228-1232
The Pharmacogenomics J. 1
Pages: 152-156
J.Biochem. 130
Pages: 535-542
130003534268
Psychogeriatrics 1
Pages: 273-276
10019049816
Int.J.Mol.Med. 5
Pages: 269-273
Cytotechnology 33
Pages: 213-219
Human Mol.Genet 9
Pages: 1393-1402
Human Mol.Genet. 9